옵션 체인은 다양한 행사가격과 만기일에 대한 Apogee Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Apogee Therapeutics에 대한 시장 심리를 평가합니다..

Apogee Therapeutics (NASDAQ:APGE) 주식, 옵션 체인

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Apogee Therapeutics Inc

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 5 years by 11.64% on an annualized basis producing an average annual return of 25.75%. Currently, Taiwan Semiconductor has a market capitalization of $855.68 billion. 
Buying $100 In TSM: If an investor had bought $100 of TSM stock 5 years ago, it would be worth $302.48 today based on a price of $164.98 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745855111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

RBC Capital analyst Conor McNamara maintains Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) with a Outperform and lowers the price target from $24 to $20.

Price Target

Analyst Ratings

AVTR

RBC Capital Maintains Outperform on Avantor, Lowers Price Target to $20

Macro Economic Events

Market Summary

Economics

NVDA

Benzinga Market Summary: S&P And Nasdaq Drop As NVIDIA Falls On Reports Huawei Has Developed Competing AI Chip, Oil Slips, Bernstein Upgrades Boeing Stock

RBC Capital analyst Matthew Swanson maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Outperform and lowers the price target from $40 to $30.

ZETA

RBC Capital Maintains Outperform on Zeta Global Holdings, Lowers Price Target to $30

RBC Capital analyst Nik Modi reiterates Reynolds Consumer Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REYN#NASDAQ">REYN</a>) with a Sector Perform and maintains $30 price target.

Reiteration

REYN

RBC Capital Reiterates Sector Perform on Reynolds Consumer Prods, Maintains $30 Price Target

RBC Capital analyst Nik Modi reiterates Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Sector Perform and maintains $9 price target.

RBC Capital Reiterates Sector Perform on Newell Brands, Maintains $9 Price Target

F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) has outperformed the market over the past 20 years by 5.27% on an annualized basis producing an average annual return of 13.29%. Currently, F5 has a market capitalization of $15.49 billion. 
Buying $100 In FFIV: If an investor had bought $100 of FFIV stock 20 years ago, it would be worth $1,197.31 today based on a price of $267.06 for FFIV at the time of writing.
<h3>F5's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745854218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FFIV

Here's How Much You Would Have Made Owning F5 Stock In The Last 20 Years

Shares of Cantor Equity Partners Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) have soared 202% to $32.76 over the past week, fueled by news of a <a href="https://www.benzinga.com/news/25/04/45010785/cantor-equity-partners-cep-stock-is-up-200-this-week-whats-happening">merger</a> with newly formed Bitcoin-focused firm Twenty One.
What To Know: The combined company, valued at $3.6 billion, is set to become the third-largest public holder of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), behind only <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45039399/strategy-buys-15355-bitcoin-for-142-billion-year-to-date-btc-yield-hits-137">Strategy</a> and Tether. Twenty One is backed by Tether, SoftBank and Jack Mallers—who will step in as CEO following the merger.
Currently, Twenty One holds 42,000 Bitcoin and has ambitious plans to continue accumulating. It recently raised $585 million to bolster its Bitcoin acquisitions and support operations. 
The firm will focus on building Bitcoin-native financial products, media platforms, and capital market tools, with unique metrics such as &#8220;Bitcoin Per Share&#8221; driving its strategy.
Once the merger is finalized, the company's shares will trade on the Nasdaq under the new ticker symbol &#8220;XXI.&#8221; The transaction still requires shareholder approval but signals a major new force in the Bitcoin investment landscape.
Read Also: <a href="https://www.benzinga.com/news/global/25/04/45038430/massive-power-outages-hit-spain-portugal-snarling-travel-investigations-into-cause-underway">Massive Power Outages Hit Spain, Portugal Snarling Travel: Investigations Into Cause Underway</a>
<h2 class="wp-block-heading">How To Buy CEP Stock</h2>
By now you're likely curious about how to participate in the market for Cantor Equity Partners &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Cantor Equity Partners, which is trading at $30.84 as of publishing time, $100 would buy you 3.05 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CEP has a 52-week high of $39.29 and a 52-week low of $9.99.

$BTC

Why Cantor Equity Partners (CEP) Stock Is Up 200% Over The Past Week

D. Boral Capital analyst Jason Kolbert maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and maintains $32 price target.

CMPX

D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target

<a href="https://in.benzinga.com/topic/security-software">Security software companies</a> Tenable Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>), Varonis Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) and Qualys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) are gearing up to report their quarterly earnings on May 6.
While security continues to be a top priority for Chief Information Officers, industry checks reveal that tariffs and currency headwinds have limited impact on security spending, according to JPMorgan.
The Security Software Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5880cc2377f9dd00011b0b74/brian-essex">Analyst Brian Essex</a> maintained ratings, while cutting price targets.
<ul>
<li>Tenable Holdings: Overweight, price target reduced from $53 to $43</li>
<li>Varonis Systems: Overweight, price target cut from $55 to $45</li>
<li>Qualys: Underweight, price target trimmed from $122 to $117</li>
</ul>
The Security Software Thesis: Although tariffs pose less of a threat on security spending,there is limited visibility into the performance of security software companies due to enterprises facing macro uncertainty, Essex said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h2 class="wp-block-heading">Tenable Holdings</h2>
The company is likely to report solid results, despite core VM (virtual machine) featuring lower in the list of enterprises' spending priorities, the analyst stated.
If Tenable Holdings beats expectations but does not pass through the outperformance to the guidance, preferring to play it safe, this would be seen as a positive, he added.
<h2 class="wp-block-heading">Varonis Systems</h2>
"We see potential for VRNS to beat SaaS expectations this quarter as the company moves to accelerate its transition this year," Essex wrote.
Management's full-year guidance is already conservative, which Varonis Systems could outperform due to its healthy fundamentals, he said.
<h2 class="wp-block-heading">Qualys</h2>
The company may deliver "another quarter of billings deceleration," given tougher comps, the analyst stated.
Management needs to remain conservative in their guidance due to Qualys'recent sales execution issues, he further said.
Price Target Reductions:
The price target for the three companies has been reduced "to reflect lower peer multiples," Essex wrote in the note.
At the time of publication on Monday, shares of:
<ul>
<li>Tenable Holdings had risen by 0.39% to $33.11</li>
<li>Varonis Systems had risen by 0.05% to $42.30</li>
<li>Qualyshad risen by 0.21% to $127.02</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/insights/analyst-ratings/25/04/45039959/expert-outlook-qualys-through-the-eyes-of-8-analysts">Expert Outlook: Qualys Through The Eyes Of 8 Analysts</a></li>
</ul>
Image: Shutterstock

Analyst Color

Previews

QLYS

TENB

VRNS

Tenable Holdings, Varonis Systems, Qualys Slashed Ahead Of Q1 Results

WIIM

SK Telecom Co. shares are trading lower. The company reported a data breach due to a cyberattack.

D. Boral Capital analyst Jason Kolbert maintains Medicus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) with a Buy and maintains $14 price target.

MDCX

D. Boral Capital Maintains Buy on Medicus Pharma, Maintains $14 Price Target

BMO Capital analyst Michael Zaremski maintains Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Market Perform and lowers the price target from $148 to $142.

GSHD

BMO Capital Maintains Market Perform on Goosehead Insurance, Lowers Price Target to $142

MicroAlgo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares are trading higher by 2.40% to $8.11 during Monday&#8217;s session, pulling back from their session high of $10.65. The company earlier reported a <a href="https://www.benzinga.com/pressreleases/25/04/g45036349/microalgo-announces-strong-net-income-and-cash-growth-in-2024-driven-by-robust-demand-for-central-">return to profitability for 2024</a>, reporting total revenues of RMB 541.5 million ($75.3 million) and net income of RMB 53.4 million ($7.3 million).
What To Know: This marks a significant turnaround from a net loss of RMB 266.2 million in 2023. The shift is credited to the company&#8217;s strategic focus on its central processing algorithm services, which contributed 100% of its revenue in 2024, after moving away from its intelligent chips and services segment. 
Ongoing investment in research and development, totaling RMB 111.7 million ($15.5 million), per the company, has helped MicroAlgo maintain its competitive edge. The company also highlighted their solutions have found growing demand in sectors like internet advertising and online gaming. 
The company additionally reported cash and cash equivalents reaching RMB 1,035.9 million ($144.1 million) by year-end, up from RMB 317 million in 2023.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45038393/whats-going-on-with-wells-fargo-stock-today">What&#8217;s Going On With Wells Fargo Stock Today?</a>
<h2 class="wp-block-heading">How To Buy MLGO Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in MicroAlgo&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, MLGO has a 52-week high of $509.60 and a 52-week low of $1.11.

MLGO

MicroAlgo (MLGO) Reports Return To Profitability In 2024: What's Going On?

BMO Capital analyst Jeffrey Silber maintains Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) with a Outperform and raises the price target from $97 to $98.

STRA

BMO Capital Maintains Outperform on Strategic Education, Raises Price Target to $98

JP Morgan analyst Michael Rehaut maintains Whirlpool (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) with a Neutral and lowers the price target from $109 to $89.

JP Morgan Maintains Neutral on Whirlpool, Lowers Price Target to $89

BMO Capital analyst James Thalacker maintains NiSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NI#NYSE">NI</a>) with a Outperform and raises the price target from $42 to $43.

BMO Capital Maintains Outperform on NiSource, Raises Price Target to $43

JP Morgan analyst John Royall maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Overweight and lowers the price target from $152 to $147.

JP Morgan Maintains Overweight on Valero Energy, Lowers Price Target to $147

BMO Capital analyst James Thalacker maintains Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) with a Outperform and raises the price target from $46 to $50.

BMO Capital Maintains Outperform on Exelon, Raises Price Target to $50

BMO Capital analyst James Thalacker maintains Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) with a Market Perform and raises the price target from $71 to $72.

BMO Capital Maintains Market Perform on Eversource Energy, Raises Price Target to $72

Health Care

Press Releases

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Comments

Apogee Therapeutics

Apogee Therapeutics (APGE) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌